TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04512417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab+Radiotherapy
Description: The combined treatment group received radiotherapy for recurring or metastatic lesions: at least one or more lesions were irradiated, stereotactic body radiotherapy (SBRT, 8Gy/time, 3-5 times) or conventional radiotherapy (parts not suitable for SBRT, total Dose 30Gy or more); start immunotherapy within 8 weeks after radiotherapy.Until PD or toxicity is intolerable or up to 24 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab,200mg,Q3W,Until PD or toxicity is intolerable or up to 24 months.
Study: NCT02692222

Intervention type: OTHER
Intervention: Calculation of PPV and CO with two methods
Study: NCT02837289

Intervention type: OTHER
Group type: OTHER
Intervention: Therapy taping
Description: Therapy taping follows an anatomical pattern from the femur until tibia for correction of dynamic valgus with therapy taping.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo taping
Description: Placebo taping follows a different anatomical path without tension, eliminating all therapeutic process elements
Study: NCT02454725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Network
Description: Leaders of social networks will undergo small group training to develop skills to convey information effectively and deliver messages endorsing regular HIV testing to members of their social networks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison
Description: All participants will receive HIV counseling and rapid testing following the Wisconsin Department of Health guidelines. Sexually active men who receive a negative test result will be told that they should be HIV-tested every three to six months, unless they have a monogamous HIV negative partner

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comparison
Description: All participants will receive HIV counseling and rapid testing following the Wisconsin Department of Health guidelines. Sexually active men who receive a negative test result will be told that they should be HIV-tested every three to six months, unless they have a monogamous HIV negative partner
Study: NCT01542320

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938
Description: 1 x 10e8 colony forming units in 5 drops (0.17ml)daily from study enrollment to study conclusion. Duration based on rotavirus vaccine administration.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution without active Lactobacillus reuteri
Study: NCT03854201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Exercise Counseling (PEC)
Description: At the first counseling appointment, PEC-participants answer the physical activity (PA) questionnaire, perform fitness tests and discuss with their exercise instructor. The target is a personalized short-term PA plan including where and when the PA/exercise takes place and what is the mode. Participants may choose instructed group-exercise sessions provided by the municipal sports/leisure sector or exercising alone as preferred. The exercise instructors utilize the fitness test results and feedback data of the research accelerometers by the UKK Institute to guide the participants. The PEC includes 2 more face-to-face sessions and 4-6 phone calls by the instructors aimed at checking the realization of exercise plans and discussing the outcomes provided by the interactive accelerometer.
Study: NCT01564914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105
Description: 10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV
Study: NCT02715180

Intervention type: RADIATION
Group type: OTHER
Intervention: low dose chest computed tomography
Description: All participants were evaluated 2 scout films during LDCT screenings. The first scout film was obtained while a participant was holding a comfortable expiration with the arms at down position, and the second scout film was obtained while a full inspiration with the arms at raised position. The axial images of LDCT were taken during participants' full inspiration. The radio-opaque marker was attached to the participants' skin where the lowest part of sternum was palpable, because the sternum moves according to the position of arms and respiration.
Study: NCT04045275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm
Description: Calm provides daily, 10-minute, guided meditations grounded in mindfulness-based stress reduction (MBSR) and Vipassana meditation. Calm also offers Sleep Stories, developed using techniques from Cognitive Behavioral Therapy and Relaxation Technique. Clam also includes behavioral components to reinforce sustained practice.
Study: NCT01446107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placement of fissure sealant
Description: placement of resin-based fissure sealant at baseline without replacement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluoride varnish
Description: topical applications of a 5% sodium fluoride (NaF) varnish onto tooth surface every 6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: silver fluoride
Description: topical applications of a 38% silver diamine fluoride (SDF) solution onto tooth surface every year

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: application of water onto tooth surface every year
Study: NCT03589833

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tripterygium Wilfordii
Description: Oral Tripterygium Wilfordii 20mg thrice daily for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tripterygium Wilfordii
Description: Oral Tripterygium Wilfordii 20mg thrice daily for 24 weeks.
Study: NCT03085368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lapatinib/herceptin
Description: Lapatinib produced by glaxosmithkline. Oral small molecule epidermal growth factor tyrosine kinase inhibitor. Mainly used for combined with capecitabine in the treatment of ErbB-2 over expression, including received prior anthracycline, paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. Our clinical trial want to see its benefit in early breast cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib/herceptin
Description: Lapatinib produced by glaxosmithkline. Oral small molecule epidermal growth factor tyrosine kinase inhibitor. Mainly used for combined with capecitabine in the treatment of ErbB-2 over expression, including received prior anthracycline, paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. Our clinical trial want to see its benefit in early breast cancer
Study: NCT03589833

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Oral methotrexate 7.5-15mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 15mg (max 0.3mg/Kg) per week in 4 weeks. Folic acid at the dose of 5 mg per week were applied to all participants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Yisaipu
Description: Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, was subcutaneously injected at a dose of 50 mg once a week for 24 weeks.
Study: NCT01863186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine HCl
Description: Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine HCl
Description: Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lofexidine-matching tablets without the active pharmaceutical ingredient will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo.

Intervention type: DRUG
Group type: OTHER
Intervention: Open Label Lofexidine HCL
Description: Lofexidine HCl tablets will are available in 0.2 mg tablets. During the optional open-label portion of the study, Lofexidine HCl can be prescribed at the discretion of the Investigator but total daily dose will not exceed 3.2 mg.
Study: NCT04193319

Intervention type: DRUG
Group type: OTHER
Intervention: Fluzoparib
Description: PARP inhibitor

Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole
Description: inhibitor
Study: NCT00781430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib (HKI-272)
Description: Neratinib 40-mg oral tablets. SINGLE DOSE of 120-mg (3 x 40-mg tablets)
Study: NCT00982631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus/PLD
Description: This is a dose escalation study. Patients will start with temsirolimus iv once weekly. After 2 weeks, PLD therapy is added. From then on, PLD is repeated every 4 weeks. One cycle is 28 days. The DLT period is also defined within the first 28 days of combination therapy (thus the first 6 weeks of study participation). The first dose level (DL) is DL 1. Depending on toxicity, intermediate dose levels can be added. If no MTD is found in the sixth cohort, this dose level will be considered as the recommended dose (RD), being the optimal dose for both drugs in this combination. At the MTD dose level, the dose level will be expanded to a total of 12 patients.
Study: NCT03087786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Bitartrate Lozenge 4mg
Description: Test Product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Polacrilex 4Mg Lozenge
Description: Active Comparator
Study: NCT01332721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC105 and Bevacizumab
Description: Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
Study: NCT00745134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03589833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yisaipu
Description: Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, was subcutaneously injected at a dose of 50 mg once a week for 24 weeks.
Study: NCT04139291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex decongestive therapy phase 1
Description: Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
Study: NCT02929732

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sympathetic nervous activity measurement
Description: Polysomnography, MIBG myocardic scintigraphy, and 24h blood pressure measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sympathetic nervous activity measurement
Description: Polysomnography, MIBG myocardic scintigraphy, and 24h blood pressure measurement
Study: NCT03045952

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation device
Description: Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.
Study: NCT04839640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bredent denture teeth
Description: composite resin denture teeth

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bredent denture teeth
Description: composite resin denture teeth
Study: NCT03815344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard
Description: 20 units diluted in 100mL of Normal Saline injected laparoscopic needle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-vaginal misoprostol
Description: 20 units diluted in 100mL of Normal Saline injected laparoscopic needle and misoprostol 400 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-vaginal misoprostol
Description: 20 units diluted in 100mL of Normal Saline injected laparoscopic needle and misoprostol 400 mcg
Study: NCT02053155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer based patient education
Study: NCT04192708

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intercostal nerve block under direct vision
Description: When the intercostal nerve is adequated exposed，a surgeon use a 5ml syringe to perform the block and the needle is tilted 15 degree cephalad and advanced towards the caudal rim of the lib，and penetration depth is about 5mm.Then 1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intercostal nerve block under ultrasound guidance
Description: After induction ，an ultrasonographic probe (M-Turbo with the L25 transducer; SonoSite Inc.) is used to scan laterally from the midaxillary line to identify the required anatomic landmarks, while the patients are in a lateral decubitus position. The ribs are identified as hyperechoic streaks, while the pleura appeared as hyperechoic lines between and below the ribs.The needle was advanced towards the caudal rim of the rib until the distal tip is just between the innermost and inner intercostal muscle.1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral block under ultrasound guidance
Description: Paravertebral block is performed between the thoracic segments T7-8,A linear ultrasound transducer (M-Turbo with the L25×transducer; SonoSite Inc.) is placed to parallel the T7 transverse process so as to identify the T7 spinous process，the T7 transverse process and 7th lib.Then move the probe caudally until the thoracic paravertebral space (TPVS) which is bounded by transverse process,pleura and internal intercostal membrane.Using in-plane technique, we advance the 20-gauge needle(Becton Dickinson Infusion Therapy Sysstems Inc.Sandy,Utah 84070,USA.1.88，1.1×48mm) until the needle tip penetrates the internal intercostal membrane,9ml mixture of 1% lidocaine and 1/200000 epinephrine after no blood or gas is aspirated.Both PVB and ultrasound-guided ICNB is performed by the same anesthesiologist
Study: NCT04434183

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exercises of rehabilitation
Description: Compare and evaluate of the effects of the routin physical medicine and rehabilitation programs in impingement patients

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exercises of rehabilitation
Description: Compare and evaluate of the effects of the routin physical medicine and rehabilitation programs in impingement patients
Study: NCT01965847

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication therapy management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication therapy management
Study: NCT02009267

Intervention type: DEVICE
Intervention: Patient controlled analgesia
Description: A programable electronically controlled infusion pump that delivers an amount of intravenous analgesic when the patient presses a button.

Intervention type: PROCEDURE
Intervention: Continuous thoracic epidural infusions
Description: Continuous thoracic epidural infusions (TE) involves continuous infusion of drugs through a catheter placed into the epidural space, resulting in a loss of sensation-including the sensation of pain-by blocking the transmission of signals through nerve fibers in or near the spinal cord.

Intervention type: PROCEDURE
Intervention: Continuous paravertebral blockade
Description: Continuous paravertebral blockade (PVB) is the technique of injecting local anesthetic adjacent to the thoracic vertebra that anesthetizes the spinal nerve roots after they exit the spinal canal.
Study: NCT01891955

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy diet A
Description: Healthy diet A will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet B. Healthy diet A will include substantial amounts of whole grains, low-fat dairy and legumes (this is called healthy diet with grains and dairy). This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy diet B
Description: Healthy diet B will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet A. Healthy diet B will exclude grains, legumes and dairy, which will largely be replaced by root vegetables, vegetables and fruit, and slightly more lean meat, fish and nuts (this is called healthy diet without grains and dairy). Salt intake will be lower in healthy diet B. This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins.
Study: NCT04704193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey of Decision Aid
Description: The decision aid will be evaluated by a survey administered to those who have used the tool.
Study: NCT01283984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2115
Description: Single dose, oral inhalation (nebuliser solution)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, oral inhalation (nebuliser solution)
Study: NCT00745134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Optional correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Optional correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study: NCT03010852

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused incentive spirometer education and monitoring
Study: NCT00705315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel as an IV infusion over 1h at the dose of 75mg/m2 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin as an IV infusion over 10 min at the dose of 75mg/m2 every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab as an IV infusion over 1h at the dose of 15 mg/kg every 3 weeks for 6 cycles
Study: NCT02402491

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 12 months of P2Y12 receptor antagonist
Description: All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24 months of P2Y12 receptor antagonist
Description: All subjects will be received 24 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: The maintenance dose of aspirin is 100 mg daily, to be taken indefinitely.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: The maintenance dose of aspirin is 100 mg daily, to be taken indefinitely.
Study: NCT03727698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Linac
Description: MR guided radiotherapy treatment
Study: NCT01121107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Atrial Pressure Monitoring System
Description: Left atrial lead is placed for ambulatory monitoring of left atrial pressure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Advisory Module
Description: Handheld device that provides medication reminders

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Advisory Module
Description: Handheld device that provides medication reminders
Study: NCT01242618

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: engineered nasal cartilage graft
Description: implantation of engineered nasal cartilage grafts in the alar lobule
Study: NCT00825864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac drops
Description: one drop 4 times a day for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone sodium phosphate 0.1% eye drops
Description: for first week after the operation : one drop 6 times a day. Then tapering by reducing one drop for a week